^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    MEN1112

    i
    Other names: MEN1112, MEN 1112, OX 357, OX-001, OBT357, OBT 357, ADC-001
    Associations

    News

    Trials
    Company:
    Menarini, Oxford BioTherapeutics
    Drug class:
    ADP-ribosyl cyclase 2 inhibitor
    Associations

    News

    Trials
    almost5years
    [VIRTUAL] MEN1112/OBT357, a first-in-class humanized de-fucosylated monoclonal antibody targeting CD157 positive cells in acute myeloid leukemia and myelodysplastic syndrome (AACR 2021)
    Importantly, we confirmed in ex vivo experiments, the depletion of these immunosuppressive cells by MEN1112/OBT357. Overall, our data demonstrate that MEN1112/OBT357 is a novel antibody with potent ex vivo activity against blast cells in AML and MDS patients, suggesting a potential contribution of MEN1112/OBT357 in altering the immunosuppressive environment in the bone marrow niche.
    IO biomarker
    |
    FCGR3A (Fc Fragment Of IgG Receptor IIIa)
    |
    MEN1112
    over5years
    CD157: From Myeloid Cell Differentiation Marker to Therapeutic Target in Acute Myeloid Leukemia. (PubMed, Cells)
    The aim of this review is to provide an overview of the immunoregulatory functions of human CD157/BST-1 in physiological and pathological conditions. We then focus on CD157 expression in hematological tumors highlighting its emerging role in the interaction between acute myeloid leukemia and extracellular matrix proteins and its potential utility for monoclonal antibody targeted therapy in this disease.
    Review • Journal
    |
    CD38 (CD38 Molecule)
    |
    MEN1112